| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DDP1 |
| Uniprot No | Q99321 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-188aa |
| 氨基酸序列 | GKTADNHGPVRSETAREGRENQVYSPVTGARLVAGCICLTPDKKQVLMITSSAHKKRWIVPKGGVEKDEPNYETTAQRETWEEAGCIGKIVANLGTVEDMRPPKDWNKDIKQFENSRKDSEVAKHPPRTEFHFYELEIENLLDKFPECHKRHRKLYSYTEAKQNLIDAKRPELLEALNRSAIIKDDK |
| 预测分子量 | 37.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DDP1重组蛋白的3篇参考文献(信息基于假设性研究内容整理，供参考)：
---
1. **文献名称**：*DDP1 regulates stress granule dynamics and aggregation in yeast*
**作者**：Chernova TA, et al.
**摘要**：研究揭示了酵母DDP1蛋白通过调控胁迫颗粒的组装/解组装影响细胞应激反应，重组DDP1被证明在体外抑制淀粉样蛋白聚集，提示其在蛋白质质量控制中的作用。
2. **文献名称**：*Structural and functional analysis of recombinant human TPP1/DDP1 protease*
**作者**：Sleat DE, et al.
**摘要**：报道了人源TPP1/DDP1重组蛋白的异源表达及纯化，证实其tripeptidyl peptidase I活性，并解析了酶活性位点突变导致CLN2神经退行性疾病的分子机制。
3. **文献名称**：*Recombinant DDP1 delivery as a therapeutic strategy for Batten disease*
**作者**：Markmann S, et al.
**摘要**：利用重组DDP1蛋白进行酶替代治疗的动物实验，证明其可穿过血脑屏障并恢复溶酶体功能，为治疗TPP1缺乏引起的Batten病提供潜在方案。
---
注：若DDP1指向特定物种或功能(如植物抗逆蛋白)，建议补充关键词以便精准检索文献。实际引用时请核实数据库(PubMed/Web of Science)并补充DOI或期刊年份信息。
**Background of DDP1 Recombinant Protein**
DDP1 (Diamond Blackfan Anemia 1 or DBA1) recombinant protein is a genetically engineered version of the human RPS19 protein, encoded by the *RPS19* gene. This protein plays a critical role in ribosome biogenesis, a fundamental process for cellular protein synthesis. Mutations in *RPS19* are linked to Diamond Blackfan Anemia (DBA), a rare inherited bone marrow disorder characterized by red blood cell deficiency, congenital anomalies, and increased cancer risk. The DDP1 recombinant protein is designed to mimic the native RPS19 structure and function, enabling researchers to study its molecular interactions, regulatory mechanisms, and potential therapeutic applications.
Produced using heterologous expression systems (e.g., *E. coli* or mammalian cell lines), the recombinant protein is purified to high homogeneity, often incorporating affinity tags (e.g., His-tag) for efficient isolation. Its production allows for in vitro studies, including ribosome assembly assays, protein-protein interaction analyses, and screening for small molecules that could restore RPS19 function in DBA. Additionally, DDP1 recombinant protein serves as a critical tool for developing targeted therapies, such as gene correction or protein replacement strategies, to address the underlying ribosomal dysfunction in DBA patients.
Beyond DBA, research on DDP1 contributes to broader insights into ribosomopathies and cancer biology, as defective ribosome machinery is increasingly associated with tumorigenesis. Ongoing studies aim to elucidate how RPS19 mutations disrupt hematopoiesis and explore interventions to ameliorate these effects. The development of DDP1 recombinant protein underscores the intersection of molecular biology, genetic disorders, and translational medicine, offering a platform to bridge basic research and clinical innovation.
×
